62 results about "Neurogenic inflammation" patented technology

The present invention provides methods for treating neuropathological states and neurogenic inflammatory states in a subject. The present invention also provides methods for identifying compounds that can be used to treat such states. Preferably, the compounds alter the distribution of NMDA glutamate receptor NR1 subunit in cells, and / or alter the production of TNF.alpha. by cells.

The invention provides compounds, compositions, methods, and kits for the treatment of neurogenic inflammation.

The invention provides compounds, compositions, methods, and kits for the treatment of pain, itch, and neurogenic inflammation.

The invention relates to a preparation method and application of a marine fungi aspergillus terreus butyrolactone compound butyrolactone-I. The invention discloses application of the marine fungi aspergillus terreus butyrolactone compound butyrolactone-I as shown in a formula (I) to preparation of medicaments for resisting to peripheral and neurogenic inflammation and resisting to neurodegenerative diseases. The formula is shown in the description. The invention finds that besides a DPPH free radical, butyrolactone-I can also well remove an ABTS free radical and an OH free radical; the marinefungi aspergillus terreus butyrolactone compound butyrolactone-I has better oxidation resistance and inflammation resistance and has better neuroprotection activity; therefore, the marine fungi aspergillus terreus butyrolactone compound butyrolactone-I has a wide application prospect in the aspect of preparing the medicaments for resisting to peripheral and neurogenic inflammation and resisting toneurodegenerative diseases. Meanwhile, by the preparation method of the butyrolactone-I, which is provided by the invention, the butyrolactone-I can be successfully prepared; the method is simple andeasy to realize large-scale production; culture conditions can also be optimized by addition of an inducer, so that yield of the butyrolactone-I is greatly improved.

A cosmetic, pharmaceutical or dermatological preparation containing extract of the plant Eperua falcata, active principles of the plant Eperua falcata, astilbin or engeletin. The preparation is useful to inhibit release of pro-imflammatory mediators and neuropeptides, including CGRP and SP, for skin and hair treatment, including, sensitive skin, acne, scalp itch and neurogenous inflammation.

The subject matter of the present invention is a cyclic or linear tetra- or pentapeptide binding to somatostatin receptors. The compounds of the invention are characterised in that they contain the radical of an amino carboxylic acid bearing a five-membered ring in the peptide backbone which may optionally contain O, S, Se, N, or P. These compounds are easy to prepare and display increased stability against peptidases. The compounds of the present invention induce apoptosis of tumour cells and the use of said compounds for cancer therapy is described. In particular, the compounds are characterised in that they are active even against tumour cells displaying resistance against other somatostatin derivatives such as octreotide. In addition, the use of the compounds of the invention for tumour diagnosis by means of positron-emission tomography is described, as well as their use as agents against neurogenic inflammation.

The present invention relates to a beta3 adrenergic receptor agonist of formula (I) or a pharmaceutical salt thereof, which is capable of increasing lipolysis and energy expenditure in cells and, therefore, is useful for treating Type II diabetes and / or obesity. The compound can also be used to lower triglyceride levels and cholesterol levels or raise high density lipoprotein levels or to decrease gut motility. In addition, the compound can be used to reduced neurogenic inflammation or as an antidepressant agent. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for decreasing gut motility are also disclosed.

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof:The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation.

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof:The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof:The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof:The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, itch, and neurogenic inflammation.

The invention relates to a pharmaceutical composition for curing rheumatoid arthritis, belonging to traditional Chinese medicines. The pharmaceutical composition comprises the following active materials in percentage by weight: 14-30 beta-eucalyptol, 12-30 inocosterone, 30-50 phellodendron total alkaloid and 30-50 coix seed alcohol extract, is used for curing symptoms, such as the damp invasion of lower energizer, foot and knee inflammation, muscle and joint pain, and the like and has the actions of clearing heat and promoting diuresis.

The present invention provides a composition for treating ischemic diseases or neurogenic inflammatory disorders, containing a secretome of neural progenitor cells (NPCs) as an active ingredient. Thesecretome of NPCs, of the present invention, reduces an ischemic injury site and enables neurological functions to recover by means of roles such as anti-inflammation, neovascularization regeneration,and activation and proliferation of inherent stem cells, thereby being usable as a therapeutic agent for ischemic diseases and degenerative nervous system disorders such as nerve damage diseases caused by inflammation. Particularly, the secretome of NPCs, of the present invention, has an excellent behavior improvement effect when administered multiple times.

The use of vitamin D3 for the manufacture of a medicament for the transdermal treatment of neurogenic inflammation and neuropathic pain (including peripheral neuropathic pain); also a method for the relief of neurogenic inflammation and neuropathic pain using this medicament.

The invention discloses an application of glycyrrhizic acid to prepare drugs for promoting medullary sheath regeneration to restrain neurogenic inflammation. Experiment proves that the glycyrrhizic acid can effectively relieve inflammatory reactions and restrain demyelinating lesion, and can relieve development of diseases courses of acute and chronic experimental autoimmuneencephalomyelitis. Theglycyrrhizic acid can promote medullary sheath regeneration in a cuprizone-induced cuprizone demyelination model, an in vitro mechanism study finds that the glycyrrhizic acid can directly regulate a GSK-3 beta signal channel to induce the polarization of oligodendroglia precursor cells, so that the mature polarization of the oligodendroglia cells can be notably promoted, and the synthesis of medullary sheath protein is stimulated. A mechanism for promoting medullary sheath regeneration by the lycyrrhizic acid proves that a new basis is provided for treating demyelinating diseases and multiplesclerosis, and clinical-usable new medicines are provided for central nervous system demyelinating diseases and the like.

The invention discloses a purpose of kinsenoside or pharmaceutically-acceptable salt thereof to preparation of medicines for preventing and treating neurogenic inflammation. The kinsenoside or the pharmaceutically-acceptable salt thereof can effectively prevent and treat the neurogenic inflammation, and can treat nervous system diseases caused by the neurogenic inflammation.

The present disclosure provides methods for alleviating or preventing the negative physiological side effects associated with the administration of EGFR blocking therapeutics. The disclosure provides, inter alia, methods for treating or preventing: hypomagnesemia, cardiac dysfunction, and skin lesions, which are induced by EGFR blocking drugs, by administering an NK-1 receptor antagonist.

The invention provides compounds of Formula (I), or pharmaceutically acceptable salts thereof. The compounds, compositions, methods and kits of the invention are useful for the treatment of pain, cough, itch, and neurogenic inflammation.

This invention provides compounds of Formula I having the structure 1 wherein, 2 ,U, V, W, X, and Y are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.